| CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells V Kozlova, A Ledererova, A Ladungova, H Peschelova, P Janovska, ... Plos one 15 (3), e0229170, 2020 | 21 | 2020 |
| Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro A Ledererova, L Dostalova, V Kozlova, H Peschelova, A Ladungova, ... Journal for Immunotherapy of Cancer 9 (8), 2021 | 20 | 2021 |
| Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia V Mancikova, H Peschelova, V Kozlova, A Ledererova, A Ladungova, ... Journal for ImmunoTherapy of Cancer 8 (1), 2020 | 12 | 2020 |
| Exploring the Mechanisms of Venetoclax Resistance Via Drug Screening and Genome-Wide CRISPR Screening A Ladungova, H Peschelova, L Dostalova, Y Lodhi, NV Gottumukkala, ... Blood 142, 5759, 2023 | | 2023 |
| Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. A Ladungová, D Buša, Y Lodhi, J Hýl, M Čulen, M Šmída | | 2023 |
| CRISPR/Cas9 technology as a useful tool in the study of chornic lymphocytic leukemia. H Peschelová, V Mančíková, L Dostálová, A Ladungová, D Škrnová, ... | | 2023 |
| P419: IDENTIFICATION OF NOVEL THERAPEUTIC OPTIONS FOR VENETOCLAX-RESISTANT AML CELLS THROUGH DRUG REPURPOSING A Ladungova, D Busa, Y Lodhi, J Hyl, M Culen, M Smida HemaSphere 6, 319-320, 2022 | | 2022 |
| P627: COMBINED DRUG AND CRISPR/CAS9 SCREENING REVEALS SPECIFIC TARGETS FOR SF3B1-AND NOTCH1-MUTATED CLL CELLS L Dostálová, A Ladungová, D Škrnová, NV Gottumukkala, Y Lodhi, ... HemaSphere 6, 526-527, 2022 | | 2022 |
| CEITEC PhD Conference B CEITEC MU | | 2022 |
| Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. A Ladungová, D Buša, Y Lodhi, J Hýl, M Čulen, M Šmída | | 2022 |
| Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. NV Gottumukkala, V Mančíková, A Ledererová, V Kozlová, L Dostálová, ... | | 2022 |
| . Drug repurposing for venetoclax-resistant acute myeloid leukemia. A Ladungová, D Buša, Y Lodhi, J Hýl, M Čulen, M Šmída | | 2022 |
| Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML Y Lodhi, A Ladungová, D Buša, H Peschelová, M Čulen, M Šmída | | 2022 |
| Prediction of novel treatment options for CLL and AML cells based on drug repurposing. A Ladungová, D Buša, H Peschelová, Y Lodhi, M Čulen, M Šmída | | 2022 |
| Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1-and NOTCH1-mutated CLL cells. L Dostálová, A Ladungová, D Škrnová, NV Gottumukkala, Y Lodhi, ... | | 2022 |
| CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy. L Dostálová, A Ledererová, V Kozlová, H Peschelová, A Ladungová, ... | | 2021 |
| In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation. L Dostálová, A Ledererová, V Kozlová, H Peschelová, A Ladungová, ... | | 2021 |
| Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs. A Ladungová, H Peschelová, V Kozlová, M Šmída | | 2021 |
| The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. H Peschelová, V Kozlová, V Mančíková, A Ladungová, V Hejret, M Šmída | | 2020 |
| Tour through the drug screening in the lab of Functional Genomics A Ladungová | | 2019 |
